Blockade of adenosine A2A receptors prevents interleukin-1β-induced exacerbation of neuronal toxicity through a p38 mitogen-activated protein kinase pathway

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Simões, Ana P ^a   Duarte, João A ^a   Agasse, Fabienne ^a   Canas, Paula M ^a   Tomé, Angelo R ^a,b   Agostinho, Paula ^a   Cunha, Rodrigo A ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

A2A receptor; Adenosine; Calcium; Interleukin 1 ; Neurodegeneration; P38 MAPK

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A2A RECEPTOR; CALCIUM; GLUTAMIC ACID; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1BETA; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NUCLEIC ACID; PROPIDIUM IODIDE; STRESS ACTIVATED PROTEIN KINASE; 5 AMINO 7 (2 PHENYLETHYL) 2 (2 FURYL)PYRAZOLO(4,3 E) 1,2,4 TRIAZOLO(1,5 C)PYRIMIDINE; 5-AMINO-7-(2-PHENYLETHYL)-2-(2-FURYL)PYRAZOLO(4,3-E)-1,2,4-TRIAZOLO(1,5-C)PYRIMIDINE; ADENOSINE A2 RECEPTOR ANTAGONIST; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL VIABILITY; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME ASSAY; ENZYME PHOSPHORYLATION; HIPPOCAMPUS; IMMUNOCYTOCHEMISTRY; MALE; NERVE CELL CULTURE; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PROTEIN LOCALIZATION; RAT; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; SYNAPTOSOME; WESTERN BLOTTING; ANIMAL; CELL CULTURE; DRUG EFFECT; FEMALE; METABOLISM; NERVE CELL; PATHOLOGY; PHYSIOLOGY; PREGNANCY; WISTAR RAT;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; CELLS, CULTURED; FEMALE; INTERLEUKIN-1BETA; MALE; MAP KINASE SIGNALING SYSTEM; NEURONS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PREGNANCY; PYRIMIDINES; RATS; RATS, WISTAR; RECEPTOR, ADENOSINE A2A; TRIAZOLES;

EID: 84865050131     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-204     Document Type: Article

References (51)

1. Graeber MB. Changing face of microglia. Science 2010, 330:783-788. 10.1126/science.1190929, 21051630.
2. Marchetti B, Abbracchio MP. To be or not to be (inflamed)-is that the question in anti-inflammatory drug therapy of neurodegenerative disorders?. Trends Pharmacol Sci 2005, 26:517-525. 10.1016/j.tips.2005.08.007, 16126283.
3. Allan SM, Rothwell NJ. Cytokines and acute neurodegeneration. Nat Rev Neurosci 2001, 2:734-744. 10.1038/35094583, 11584311.
4. Lynch MA. Age-related neuroinflammatory changes negatively impact on neuronal function. Front Aging Neurosci 2010, 1:6. 2874409, 20552057.
5. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56. 10.1038/nrn2297, 2919277, 18073775.
6. Chaparro-Huerta V, Rivera-Cervantes MC, Flores-Soto ME, Gomez-Pinedo U, Beas-Zarate C. Proinflammatory cytokines and apoptosis following glutamate-induced excitotoxicity mediated by p38 MAPK in the hippocampus of neonatal rats. J Neuroimmunol 2005, 165:53-62. 10.1016/j.jneuroim.2005.04.025, 15972237.
7. Ma XC, Gottschall PE, Chen LT, Wiranowska M, Phelps CP. Role and mechanisms of interleukin-1 in the modulation of neurotoxicity. Neuroimmunomodulation 2002, 10:199-207. 10.1159/000068322, 12584407.
8. Stone TW, Behan WM. Interleukin-1beta but not tumor necrosis factor-alpha potentiates neuronal damage by quinolinic acid: protection by an adenosine A2A receptor antagonist. J Neurosci Res 2007, 85:1077-1085. 10.1002/jnr.21212, 17304576.
9. Barone FC, Irving EA, Ray AM, Lee JC, Kassis S, Kumar S, Badger AM, Legos JJ, Erhardt JA, Ohlstein EH, Hunter AJ, Harrison DC, Philpott K, Smith BR, Adams JL, Parsons AA. Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia. Med Res Rev 2001, 21:129-145. 10.1002/1098-1128(200103)21:2<129::AID-MED1003>3.0.CO;2-H, 11223862.
10. Gao Y, Signore AP, Yin W, Cao G, Yin XM, Sun F, Luo Y, Graham SH, Chen J. Neuroprotection against focal ischemic brain injury by inhibition of c-Jun N-terminal kinase and attenuation of the mitochondrial apoptosis-signaling pathway. J Cereb Blood Flow Metab 2005, 25:694-712. 10.1038/sj.jcbfm.9600062, 15716857.
11. Borsello T, Forloni G. JNK signalling: a possible target to prevent neurodegeneration. Curr Pharm Des 2007, 13:1875-1886.
12. Munoz L, Ammit AJ. Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology 2010, 58:561-568. 10.1016/j.neuropharm.2009.11.010, 19951717.
13. Gardoni F, Boraso M, Zianni E, Corsini E, Galli CL, Cattabeni F, Marinovich M, Di Luca M, Viviani B. Distribution of interleukin-1 receptor complex at the synaptic membrane driven by interleukin-1beta and NMDA stimulation. J Neuroinflammation 2011, 8:14. 10.1186/1742-2094-8-14, 3045339, 21314939.
14. Zhang R, Sun L, Hayashi Y, Liu X, Koyama S, Wu Z, Nakanishi H. Acute p38-mediated inhibition of NMDA-induced outward currents in hippocampal CA1 neurons by interleukin-1beta. Neurobiol Dis 2010, 38:68-77. 10.1016/j.nbd.2009.12.028, 20060906.
15. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994, 330:613-622. 10.1056/NEJM199403033300907, 7905600.
16. Cunha RA. Different cellular sources and different roles of adenosine: A1 receptor-mediated inhibition through astrocytic-driven volume transmission and synapse-restricted A2A receptor-mediated facilitation of plasticity. Neurochem Int 2008, 52:65-72. 10.1016/j.neuint.2007.06.026, 17664029.
17. Chen JF, Sonsalla PK, Pedata F, Melani A, Domenici MR, Popoli P, Geiger JD, Lopes LV, de Mendonca A. Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and " fine tuning" modulation. Prog Neurobiol 2007, 83:310-331. 10.1016/j.pneurobio.2007.09.002, 18023959.
18. Cunha RA. Neuroprotection by adenosine in the brain: from A1 receptor activation to A2A receptor blockade. Purinergic Signal 2005, 1:111-134. 10.1007/s11302-005-0649-1, 2096528, 18404497.
19. Sperlagh B, Baranyi M, Hasko G, Vizi ES. Potent effect of interleukin-1 beta to evoke ATP and adenosine release from rat hippocampal slices. J Neuroimmunol 2004, 151:33-39. 10.1016/j.jneuroim.2004.02.004, 15145601.
20. Zhu G, Okada M, Yoshida S, Mori F, Hirose S, Wakabayashi K, Kaneko S. Involvement of Ca2+-induced Ca2+ releasing system in interleukin-1beta-associated adenosine release. Eur J Pharmacol 2006, 532:246-252. 10.1016/j.ejphar.2005.12.085, 16487508.
21. Rebola N, Simões AP, Canas PM, Tomé AR, Andrade GM, Barry CE, Agostinho PM, Lynch MA, Cunha RA. Adenosine A2A receptors control neuroinflammation and consequent hippocampal neuronal dysfunction. J Neurochem 2011, 117:100-111. 10.1111/j.1471-4159.2011.07178.x, 21235574.
22. Sitkovsky MV, Ohta A. The 'danger' sensors that STOP the immune response: the A2A adenosine receptors?. Trends Immunol 2005, 26:299-304. 10.1016/j.it.2005.04.004, 15922945.
23. Yu L, Shen HY, Coelho JE, Araujo IM, Huang QY, Day YJ, Rebola N, Canas PM, Rapp EK, Ferrara J, Taylor D, Muller CE, Linden J, Cunha RA, Chen JF. Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol 2008, 63:338-346. 10.1002/ana.21313, 18300283.
24. Orr AG, Orr AL, Li XJ, Gross RE, Traynelis SF. Adenosine A2A receptor mediates microglial process retraction. Nat Neurosci 2009, 12:872-878. 10.1038/nn.2341, 2712729, 19525944.
25. Dai SS, Zhou YG, Li W, An JH, Li P, Yang N, Chen XY, Xiong RP, Liu P, Zhao Y, Shen HY, Zhu PF, Chen JF. Local glutamate level dictates adenosine A2A receptor regulation of neuroinflammation and traumatic brain injury. J Neurosci 2010, 30:5802-5810. 10.1523/JNEUROSCI.0268-10.2010, 20410132.
26. Silva CG, Porciúncula LO, Canas PM, Oliveira CR, Cunha RA. Blockade of adenosine A2A receptors prevents staurosporine-induced apoptosis of rat hippocampal neurons. Neurobiol Dis 2007, 27:182-189. 10.1016/j.nbd.2007.04.018, 17596953.
27. Canas PM, Porciuncula LO, Cunha GM, Silva CG, Machado NJ, Oliveira JM, Oliveira CR, Cunha RA. Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. J Neurosci 2009, 29:14741-14751. 10.1523/JNEUROSCI.3728-09.2009, 19940169.
28. Kelly A, Vereker E, Nolan Y, Brady M, Barry C, Loscher CE, Mills KH, Lynch MA. Activation of p38 plays a pivotal role in the inhibitory effect of lipopolysaccharide and interleukin-1 beta on long term potentiation in rat dentate gyrus. J Biol Chem 2003, 278:19453-19462. 10.1074/jbc.M301938200, 12609991.
29. Rebola N, Canas PM, Oliveira CR, Cunha RA. Different synaptic and subsynaptic localization of adenosine A2A receptors in the hippocampus and striatum of the rat. Neuroscience 2005, 132:893-903. 10.1016/j.neuroscience.2005.01.014, 15857695.
30. Taishi P, Bredow S, Guha-Thakurta N, Obál F, Krueger JM. Diurnal variations of interleukin-1 beta mRNA and beta-actin mRNA in rat brain. J Neuroimmunol 1997, 75:69-74. 10.1016/S0165-5728(97)00002-7, 9143239.
31. Phillips GR, Huang JK, Wang Y, Tanaka H, Shapiro L, Zhang W, Shan WS, Arndt K, Frank M, Gordon RE, Gawinowicz MA, Zhao Y, Colman DR. The presynaptic particle web: ultrastructure, composition, dissolution, and reconstitution. Neuron 2001, 32:63-77. 10.1016/S0896-6273(01)00450-0, 11604139.
32. Lopes LV, Halldner L, Rebola N, Johansson B, Ledent C, Cher JF, Fredholm BB, Cunha RA. Binding of the prototypical adenosine A(2A) receptor agonist CGS 21680 to the cerebral cortex of adenosine A(1) and A(2A) receptor knockout mice. Br J Pharmacol 2004, 141:1006-1014. 10.1038/sj.bjp.0705692, 1574266, 14993095.
33. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, Bazan NG, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Castedo M, Cidlowski JA, Ciechanover A, Cohen GM, De Laurenzi V, De Maria R, Deshmukh M, Dynlacht BD, El-Deiry WS, Flavell RA, Fulda S, Garrido C, Golstein P, Gougeon ML, Green DR, Gronemeyer H, Hajnóczky G, Hardwick JM, Hengartner MO, Ichijo H, Jäättelä M, Kepp O, Kimchi A, Klionsky DJ, Knight RA, Kornbluth S, Kumar S, Levine B, Lipton SA, Lugli E, Madeo F, Malomi W, Marine JC, Martin SJ, Medema JP, Mehlen P, Melino G, Moll UM, Morselli E, Nagata S, Nicholson DW, Nicotera P, Nuñez G, Oren M, Penninger J, Pervaiz S, Peter ME, Piacentini M, Prehn JH, Puthalakath H, Rabinovich GA, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Scorrano L, Simon HU, Steller H, Tschopp J, Tsujimoto Y, Vandenabeele P, Vitale I, Vousden KH, Youle RJ, Yuan J, Zhivotovsky B, Kroemer G. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ 2009, 16:1093-1107. 10.1038/cdd.2009.44, 2757140, 19373242.
34. Resende R, Pereira C, Agostinho P, Vieira AP, Malva JO, Oliveira CR. Susceptibility of hippocampal neurons to Aβ peptide toxicity is associated with perturbation of Ca2+ homeostasis. Brain Res 2007, 1143:11-21.
35. Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol 2005, 5:629-640. 10.1038/nri1664, 16034365.
36. Ericsson A, Liu C, Hart RP, Sawchenko PE. Type 1 interleukin-1 receptor in the rat brain: distribution, regulation, and relationship to sites of IL-1-induced cellular activation. J Comp Neurol 1995, 361:681-698. 10.1002/cne.903610410, 8576422.
37. Konsman JP, Vigues S, Mackerlova L, Bristow A, Blomqvist A. Rat brain vascular distribution of interleukin-1 type-1 receptor immunoreactivity: relationship to patterns of inducible cyclooxygenase expression by peripheral inflammatory stimuli. J Comp Neurol 2004, 472:113-129. 10.1002/cne.20052, 15024756.
38. Wong ML, Licinio J. Localization of interleukin 1 type I receptor mRNA in rat brain. Neuroimmunomodulation 1994, 1:110-115. 10.1159/000097143, 7489320.
39. Yabuuchi K, Minami M, Katsumata S, Satoh M. Localization of type I interleukin-1 receptor mRNA in the rat brain. Mol Brain Res 1994, 27:27-36. 10.1016/0169-328X(94)90180-5, 7877451.
40. Ravizza T, Boer K, Redeker S, Spliet WG, van Rijen PC, Troost D, Vezzani A, Aronica E. The IL-1beta system in epilepsy-associated malformations of cortical development. Neurobiol Dis 2006, 24:128-143. 10.1016/j.nbd.2006.06.003, 16860990.
41. Viviani B, Bartesaghi S, Gardoni F, Vezzani A, Behrens MM, Bartfai T, Binaglia M, Corsini E, Di Luca M, Galli CL, Marinovich M. Interleukin-1 beta enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. J Neurosci 2003, 23:8692-8700.
42. Balosso S, Maroso M, Sanchez-Alavez M, Ravizza T, Frasca A, Bartfai T, Vezzani A. A novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1beta. Brain 2008, 131:3256-3265. 10.1093/brain/awn271, 2724908, 18952671.
43. Murray CA, McGahon B, McBennett S, Lynch MA. Interleukin-1 beta inhibits glutamate release in hippocampus of young, but not aged, rats. Neurobiol Aging 1997, 18:343-348. 10.1016/S0197-4580(97)80317-X, 9263201.
44. Fogal B, Hewett SJ. Interleukin-1 beta: a bridge between inflammation and excitotoxicity?. J Neurochem 2008, 106:1-23.
45. Giacomello M, Drago I, Pizzo P, Pozzan T. Mitochondrial Ca2+ as a key regulator of cell life and death. Cell Death Differ 2007, 14:1267-1274. 10.1038/sj.cdd.4402147, 17431419.
46. Gomes CV, Kaster MP, Tomé AR, Agostinho PM, Cunha RA. Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Biochim Biophys Acta 2011, 1808:1380-1399. 10.1016/j.bbamem.2010.12.001, 21145878.
47. Cunha RA, Sebastião AM. Adenosine and adenine nucleotides are independently released from both the nerve terminals and the muscle fibres upon electrical stimulation of the innervated skeletal muscle of the frog. Pflügers Arch Eur J Physiol 1993, 424:503-510.
48. Coleman P, Federoff H, Kurlan R. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology 2004, 63:1155-1162. 10.1212/01.WNL.0000140626.48118.0A, 15477531.
49. Waites CL, Garner CC. Presynaptic function in health and disease. Trends Neurosci 2011, 34:326-337. 10.1016/j.tins.2011.03.004, 21596448.
50. Melani A, Gianfriddo M, Vannucchi MG, Cipriani S, Baraldi PG, Giovannini MG, Pedata F. The selective A2A receptor antagonist SCH 58261 protects from neurological deficit, brain damage and activation of p38 MAPK in rat focal cerebral ischemia. Brain Res 2006, 1073-1074:470-480.
51. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787-795. 10.1038/nature05292, 17051205.